News & Publications for:

Mark Sands

Cell-Type-Specific Profiling of Alternative Translation Identifies Regulated Protein Isoform Variation in the Mouse Brain

Posted on January 22, 2019

Darshan Sapkota, Allison M. Lake, Wei Yang, Chengran Yang, Hendrik Wesseling, Amanda Guise, Ceren Uncu, Jasbir S. Dalal, Andrew W. Kraft, Jin-Moo Lee, Mark S. Sands, Judith A. Steen, Joseph D. Dougherty. Cell Reports, Volume 26, Issue 3, 15 January 2019, Pages 594-607.e7
Read More

Posted in: HPAN, Lysosome, Neurodegeneration, Neurogenetics & Transcriptomics, Neurovascular Injury & Repair, Pilot Projects, Publications Faculty: , ,

Compromised astrocyte function and survival negatively impact neurons in infantile neuronal ceroid lipofuscinosis

Posted on October 31, 2018

Jenny Lange, Luke J. Haslett, Emyr Lloyd-Evans, Jennifer M. Pocock, Mark S. Sands, Brenda P. Williams and Jonathan D. Cooper. Acta Neuropathologica Communications, Volume 6, Issue 1, 8 August 2018, Page 74 Read More

Posted in: HPAN, Lysosome, Neurodegeneration, Publications Faculty:

Clinically early-stage CSPα mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss

Posted on October 20, 2016

Benitez BA, Cairns NJ, Schmidt RE, Morris JC, Norton JB, Cruchaga C, Sands MS. Acta Neuropathol Commun. 2015 Nov 26;3:73. PMID: 26610600 Read More

Posted in: HPAN, Lysosome, Neurodegeneration, Neurogenetics, Pilot Projects, Publications Faculty: , , ,

An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis

Posted on October 20, 2014

Macauley S, Wong AMS, Shyng C, Augner DP, Dearborn JT, Yewande P, Roberts MS, Fowler SC, Cooper JD, Watterson DM, Sands MS; The Journal of Neuroscience, Volume 34 (39), September 2014, p13077-13082 Read More

Posted in: HPAN, Neurodegeneration, Publications Faculty: